OTC · PURE
Consumer Defensive · Household & Personal Products
$0.07
Down-$0.00 (-0.14%)
Updated Sep 11, 2026, 2:03 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PURE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PURE.
PURE research
Company profile and research snapshot.
PURE BIOSCIENCE
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jun 15, 2026
PURE Bioscience (OTC:PURE) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $506.000 thousand in sales this quarter. This is a 3.05 percent increase
Benzinga · Mar 16, 2026
PURE Bioscience (OTC:PURE) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $443.000 thousand in sales this quarter. This is a 13.30 percent increase
businesswire.com · Nov 19, 2025
EL CAJON, Calif.--(BUSINESS WIRE)---- $PURE #Antimicrobial--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company has appointed Jeff Kitchell as President, in addition to his ongoing responsibilities as Corporate Secretary, and Dolana Blount as Vice President of Operations, in addition to her ongoing responsibilities as Vice President of Regulatory Affairs, in each case, effective as of November 17.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PURE.
